Infliximab is an anti-tumour necrosis factor (TNF)-alpha chimeric monoclonal antibody which is effective in diseases associated with a T-helper (Th) 1 response, such as rheumatoid arthritis, Crohn's disease and psoriasis. There are sporadic case reports of atopic dermatitis (AD) induced or precipitated by anti-TNF-alpha therapy, which have been attributed to the switch towards Th2-mediated reactions. We report the case of a 30-year-old man with long-standing severe AD associated with contact allergy and poorly responding to conventional treatments. The use of infliximab resulted in a dramatic amelioration of AD lesions and pruritus, persisting at follow-up examinations over a 3-year period. Probably, the unexpected response to infliximab therapy in this case might be due to some peculiar features of AD in our patient (i.e. chronic-continuous course and concomitant contact allergy) which could have been responsible for a more preponderant recruitment of Th1 cells as compared to “common” forms of AD.
MainiR., St ClairE.W., BreedveldF., FurstD., KaldenJ., WeismanM., SmolenJ., EmeryP., HarrimanG., FeldmanF. and LipskyP.1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.Lancet354:1932.
2.
GarnettW.R. and YunkerN.2001. Treatment of Crohn's disease with infliximab.Am. J. Health Syst. Pharm.58:307.
3.
ChaudariU., RomanoP., MulcahyL.D., DooleyL.T., BakerD.G. and GottliebA.B.2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.Lancet357:1842.
4.
AntoniC. and MangerB.2002. Infliximab for psoriasis and psoriatic arthritis.Clin. Exp. Rheumatol.20:122.
5.
CassanoN., LoconsoleF., AmorusoA., CovielloC., FilieriM., FiloticoR., Del VecchioS. and VenaG.A.2004. Infliximab monotherapy for refractory psoriasis: preliminary results.Int. J. Immunopathol. Pharmacol.17:373.
ManggeH., GindlS., KenzianH. and SchauensteinK.2003. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy.J. Rheumatol.30:2506.
8.
ChanJ.L., Davis-ReedL. and KimballA.B.2004. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy.J. Drugs Dermatol.3:315.
9.
HsuC.T., LinY.T., YangY.H. and ChiangB.L.2004. The hyperimmunoglobulin E syndrome.J. Microbiol. Immunol. Infect.37:121.
10.
HanifinJ.M. and RajkaG.1980. Diagnostic features of atopic dermatitis.Acta Derm. Venereol.92(S):44.
11.
European Task Force on Atopic Dermatitis.1993. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis.Dermatology186:23.
12.
LocksleyR.M., KilleenN. and LenardoM.J.2001. The TNF and TNF receptor superfamilies: integrating mammalian biology.Cell104:487.
13.
BannoT., GazelA. and BlumenbergM.2004. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling.J. Biol. them.279:32633.
14.
WangT.N., ChenW.Y., WangT.H., ChenC.J., HuangL.Y. and KoY.C.2004. Gene-gene synergistic effect on atopic asthma: tumour necrosis factor-alpha-308 and lymphotoxin-alpha-Ncol in Taiwan's children.Clin. Exp. Allergy34:184.
15.
GossetP., TsicopoulosA., WallaertB., VannimenusC., JosephM., TonnelA.B. and CapronA.1991. Increased secretion of tumour necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction.J. Allergy Clin. Immunol.88:561.
16.
YingS., RobinsonD.S., VarneyV., MengQ., TsicopoulosA., MoqbclR., DurhamS.R., KayA.B. and HamidQ.1991. TNF alpha mRNA expression in allergic inflammation.Clin. Exp. Allergy21:745.
17.
de VriesI.J., Langeveld-WildschutE.G., van ReijsenF.C., DuboisG.R., van den HoekJ.A., BihariI.C., van WichenD., de WegerR.A., KnolE.F., ThepenT. and Bruijnzeel-KoomenC.A.1998. Adhesion molecule expression on skin endothelia in atopic dermatitis: effects of TNF-alpha and IL-4.J. Allergy Clin. Immunol.102:461.
18.
AckermannL. and HarvimaI.T.1998. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis.Arch. Dermatol. Res.290:353.
19.
SumimotoS., KawaiM., KasajimaY. and HamamotoT.1992. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis.Arch. Dis. Child.67:277.
20.
TakahashiT., SasakiY., HamaK., FurueM. and IshibashiY.1992. Production of IL-4, IL-2, IFN-gamma, and TNF-alpha by peripheral blood mononuclear cells of patients with atopic dermatitis.J. Dermatol. Sci.3:172.
21.
LaanM.P., KoningH., BaertM.R., OranjeA.P., BuurmanW.A., SavelkoulH.F. and NeijensH.J.1998. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children.Allergy53:51.
22.
BunikowskiR., GerholdK., BrautigamM., HamelmannE., RenzH. and WahnU.2001. Effect of low-dose cyclosporin a microemulsion on disease severity, interleukin-6, interleukin-8 and tumor necrosis factor alpha production in severe pediatric atopic dermatitis.Int. Arch. Allergy Immunol.125:344.
23.
BengtssonA., HolmL., BackO., FranssonJ. and ScheyniusA.1997. Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD).Clin. Exp. Immunol.109:533.
24.
VillagomezM.T., BaeS.J., OgawaI., TakenakaM. and KatayamaI.2004. Tumour necrosis factor-alpha but not interferon-gamma is the main inducer of inducible protein-10 in skin fibroblasts from patients with atopic dermatitis.Br. J. Dermatol.150:910.
25.
FrydasS., KaragouniE., HatzistilianouM., KempurajD., ComaniS., PetrarcaC., IezziT., VernaN., ContiP. and CastellaniM.L.2004. Cytokines and allergic disorders: revisited study.Int. J. Immunopathol. Pharmacol.17:233.
26.
VernaN., CavallucciE., Di StefanoF., RamondoS., PaoliniF., CarusoR., GranaM., MarianoM., SchiavoneC., PaganelliR. and Di CioacchinoM.2002. Cyclosporin-A in allergic diseases.Int. J. Immunopathol. Pharmacol.15(S):29.
27.
PerisK., FargnoliM.C., MordentiC., ChimentiM.S. and ChimentiS.2002. Cyclosporin A for treatment of psoriasis.Int. J. Immunopathol. Pharmacol.15(S):35.
28.
MasciS. and AndreassiM.2002. Atopic dermatitis and cyclosporin.Int. J. Immunopathol. Pharmacol.15(S):41.
29.
ThepenT., Langeveld-WildschutE.G., BihariI.C., van WichenD.F., van ReijsenF.C., MuddeG.C. and Bruijnzeel-KoomenC.A.1996. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study.J. Allergy Clin. Immunol.97:828.
30.
WerfelT., MoritaA., GreweM., RenzH., WahnU., KrutmannJ. and KappA.1996. Allergen-specificity of skin-infiltrating T-cells is not restricted to a type 2 cytokine pattern in chronic skin lesions of atopic dermatitis.J. Invest. Dermatol.107:871.
31.
GreweM., Bruijnzeel-KoomenC.A., SchopfE., ThepenT., Langeveld-WildschutA.G., RuzickaT. and KrutmannJ.1998. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis.Immunol. Today19:359.
32.
ChenL., MartinezO., OverberghL., MathieuC., PrabhakarB.S. and ChanL.S.2004. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model.Clin. Exp. Immunol.138:375.
33.
RomagnaniS.Th1 and Th2 in human diseases.1996. Clin. Immunol. Immunopathol.80:225.
34.
GirolomoniG., SebastianiS., AlbanesiC. and CavaniA.2001. T-cell subpopulations in the development of atopic and contact allergy.Curr. Opin. Immunol.13:733.
35.
LisbyS., MullerK.M., JongeneelC.V., SauratJ.H. and HauserC.1995. Nickel and skin irritants up-regulate tumor necrosis factor-alpha mRNA in keratinocytes by different but potentially synergistic mechanisms.Int. Immunol.7:343.
36.
BeckeF.M., HehlgansT., BrockhoffG. and MannelD.N.2001. Development of allergic contact dermatitis requires activation of both tumor necrosis factor-receptors.Eur. Cytokine Netw.12:45.
37.
WestphalG.A., SchnuchA., MoessnerR., KonigI.R., KrankeB., HallierE., ZieglerA. and ReichK.2003. Cytokine gene polymorphisms in allergic contact dermatitis.Contact Dermatitis48:93.
